progesterone · Ferring Pharms Inc · NDA 201110
Milprosa
Earliest generic entry, as listed
21 Jan 2030
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8580293. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8580293 | use U-2810 | 21 Jan 2030 |
| US 10537584 | product | 3 Feb 2029 |
| US 10548904 | use U-2810 | 3 Feb 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 201110 · 001 · RLD · discontinued | system, vaginal | 1.78GM | 21 Jan 2030 |